Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343277 · ClinicalTrials.gov registry record · Phase 3
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
A Phase 3 study of Advanced Liposarcoma or Leiomyosarcoma, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 579
- Enrollment target
- 20
- Study locations
NCT01343277 is a Phase 3 study of Advanced Liposarcoma or Leiomyosarcoma that has completed, run by Janssen Research & Development. The registered enrollment target is 579 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT01343277, a Phase 3 study of Advanced Liposarcoma or Leiomyosarcoma, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 579 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
Conditions Studied
Interventions
- DRUG Dacarbazine
- DRUG Trabectedin
Study Locations (20)
California
- - La Jolla
- - Los Angeles
- - San Diego
- - San Francisco
- - Santa Monica
Florida
- - Boynton Beach
- - Hollywood
- - Miami
- - Orlando
- - Tampa
Georgia
- - Atlanta
- - Augusta
- - Savannah
Arizona
- - Phoenix
- - Tucson
Colorado
- - Aurora
- - Denver
Connecticut
- - Hartford
- - New Haven
Arkansas
- - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01343277
The ClinicalTrials.gov registry entry for NCT01343277 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Liposarcoma or Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Dacarbazine is the first listed.
NCT01343277 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01343277 about?
NCT01343277 is a clinical study titled "A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma". The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
What is the current status of trial NCT01343277?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 579 participants. The study started on 2011-06. Estimated completion is 2016-04.
What conditions does trial NCT01343277 study?
This clinical trial studies the following conditions: Advanced Liposarcoma or Leiomyosarcoma.
What interventions are being tested in trial NCT01343277?
The interventions under investigation include: Dacarbazine (DRUG), Trabectedin (DRUG).
Who is sponsoring clinical trial NCT01343277?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01343277 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.